Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Sdrobolini, A."'
Autor:
Fabio Trippa, Ernesto Maranzano, Andrea Sdrobolini, Sara Terenzi, Alessandra Bassetti, Alessandro Di Marzo, Paola Anselmo, Fabio Arcidiacono, Lorena Draghini, Silvio Sivolella
Publikováno v:
Tumori Journal. 106:NP63-NP66
Introduction: Oligometastatic disease has emerged as an intermediate state between localized and systemic cancer. Improvements in diagnostic modalities such as functional imaging allow a greater frequency of oligometastases diagnosis. Patients with s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e11f038df1323ef946390da8a32506fe
https://doi.org/10.1177/0300891620952852
https://doi.org/10.1177/0300891620952852
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zeuli, M. *, Di Costanzo, F., Sdrobolini, A., Gasperoni, S., Paoloni, F.P., Carpi, A., Moscetti, L., Cherubini, R., Cognetti, F.
Publikováno v:
In Annals of Oncology December 2001 12(12):1737-1741
Autor:
Canaletti R, Di Costanzo F, A. Sdrobolini, Olmeo N, S. Angiona, Silvia Gasperoni, A. Contu, F. Pucci, C. Rodinò, S. Zironi, Luppi G, Cavicchi F
Publikováno v:
American Journal of Clinical Oncology: Cancer Clinical Trial. 23:314-318
The objective of this trial was to evaluate the activity and tolerability of biomodulation of 5-fluorouracil by leucovorin, methotrexate, and platinum in patients with advanced measurable disease. Thirty-five patients with histologically or cytologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27a90a08577be9c06a415faf29ae98a
https://doi.org/10.1097/00000421-200006000-00022
https://doi.org/10.1097/00000421-200006000-00022
Publikováno v:
Tumori Journal. 85:47-53
Adenocarcinoma of the pancreas is the cause of 3-4% of cancer related deaths in Italy and over 80% of all patients exhibit advanced disease. Treatment with surgery and chemio-radio-therapy may have meaningful results in resectable and locoregional tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4681e9b05dd97fee167cf51fd2a5d0ba
https://doi.org/10.1177/030089169908501s12
https://doi.org/10.1177/030089169908501s12
Autor:
Andrea, Sdrobolini
Publikováno v:
I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]. 3(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b4b692d40fbef564d58a320dedf25b5b
https://pubmed.ncbi.nlm.nih.gov/15206220
https://pubmed.ncbi.nlm.nih.gov/15206220
Autor:
R. Cherubini, F. Di Costanzo, F. P. Paoloni, M. Zeuli, Francesco Cognetti, Luca Moscetti, A. Sdrobolini, A. Carpi, Silvia Gasperoni
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(12)
Summary Purpose Capecitabine and oxaliplatin are both active anti-cancer agents in the treatment of patients with advanced colorectal cancer (ACRC). The aim of this dose-finding trial was to determine the maximum-tolerated dose (MTD), the dose-limiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ea242f3c7917896a9c024193869d8c
https://pubmed.ncbi.nlm.nih.gov/11843252
https://pubmed.ncbi.nlm.nih.gov/11843252
Autor:
A. Sdrobolini, Campisi C, Di Costanzo F, S. Angiona, F Recchia, Raffaele M, Maria Teresa Ionta, Olmeo N, Gebbia, Adriana Romiti, S. Ortu, Silverio Tomao, A. Contu, Silvia Gasperoni, Iannelli A, Bruno Massidda
Publikováno v:
Scopus-Elsevier
Aim This phase II trial evaluated the biomodulation of 5-fluorouracil (5-FU) plus folinic acid (FA) with or without ifosfamide (IFO) in chemotherapy-naive patients with colorectal cancer. Patients and methods Forty-eight patients were randomized to r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524e48f42bbd23c43edbec8d75411bdf
https://pubmed.ncbi.nlm.nih.gov/10939601
https://pubmed.ncbi.nlm.nih.gov/10939601
Publikováno v:
Critical reviews in oncology/hematology. 35(2)
Capecitabine (Xeloda)® was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU. Capecitabine passes unchanged through the gastrointestinal tract and is metabolised in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c61f9fe39b38270199346575c14d42
https://pubmed.ncbi.nlm.nih.gov/10936467
https://pubmed.ncbi.nlm.nih.gov/10936467
Publikováno v:
Minerva medica. 90(7-8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b36d39d8ce58909d99deb8c10941dd42
https://pubmed.ncbi.nlm.nih.gov/10719427
https://pubmed.ncbi.nlm.nih.gov/10719427